Comparison of the efficacy of tenofovir and entecavir for the treatment of nucle

StephenW

Turk J Gastroenterol. 2012 Jun;23(3):247-252.
Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
DO 286 An MB, Kara B, G 220 M 220 Rd 220 L 220 YK, Soylu A, Akin MS.
Source
Adana Numune Training and Research Hospital, Gastroenterology, Seyhan / Adana, Turkey. [email protected].

Abstract
Background/aims: Chronic hepatitis B virus infection is an important cause of morbidity and mortality. Tenofovir disoproxil fumarate and entecavir were licensed for the treatment of hepatitis B virus infection. We evaluated the first 12 months of chronic hepatitis B treatments with tenofovir and entecavir and compared their efficiencies. Methods: The study enrolled 94 chronic hepatitis B patients with compensated liver disease. The entecavir group consisted of 29 patients who received entecavir 0.5 mg/day and the tenofovir group consisted of 65 patients who received tenofovir 245 mg/day. There was no statistically significant demographic or HBeAg status difference between the groups. Patients returned to the clinic every four weeks for laboratory assessments of serum chemical and hematologic values, liver function and for documentation of any adverse events. Hepatitis B serologic markers and HBV-DNA levels were assessed every 12 weeks. The primary efficacy endpoint was a plasma HBV-DNA level of less than 400 copies/ml over 48 weeks. Results: At the end of 48 weeks, treatment with either tenofovir or entecavir resulted in clinically important suppression of HBV-DNA, as 71.3%. There was no statistical difference in inducing undetectable levels of HBV-DNA between the entecavir (69%) and tenofovir (72.3%) groups. Furthermore, no side effect as an increase in creatinine was seen. HBeAg seroconversion was seen in only one patient in the entecavir group, but in no patients of the tenofovir group. Conclusions: In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir. Both drugs are safe and efficacious for patients infected with HBV.

StephenW

土耳其人胃肠。 2012军; 23（3）:247-252。
泰诺福韦和恩替卡韦治疗核苷（酸）IDE天真与慢性乙型肝炎患者的疗效比较
做一个MB的286，卡拉乙，Ğ220米220路220升220 YK，Soylu一个，类似于MS。
源

的阿达纳Numune培训和研究医院，消化科，塞伊汉/阿达纳，土耳其。 [email protected]。
抽象

背景/目的：慢性乙肝病毒感染的发病率和死亡率的重要原因。富马酸替诺福韦酯和恩替卡韦治疗乙肝病毒感染许可。我们评估泰诺福韦和恩替卡韦治疗慢性肝炎与B处理的首12个月相比，他们的效率。方法：该研究纳入94慢性乙肝代偿性肝脏疾病的患者。恩替卡韦组29例患者接受恩替卡韦0.5 mg /天，替诺福韦组包括65例谁收到替诺福韦880 mg /天。有没有统计显着的人口或HBeAg的地位有所不同群体之间的。患者返回诊所每四个星期，血清化学和血液值，肝功能和文件的任何不良事件的实验室评估。乙肝血清学标志和HBV-DNA水平进行了评估，每12个星期。主要疗效终点是等离子，HBV-DNA水平低于400拷贝/毫升超过48周。结果：在48周结束时，无论是替诺福韦或恩替卡韦治疗在临床上重要的HBV-DNA的抑制，为71.3％。诱导之间的恩替卡韦（69％）和替诺福韦组（72.3％），HBV-DNA检测不到的水平并没有显着差异。此外，被认为没有副作用增加肌酐。有人看见只有一个病人在恩替卡韦组HBeAg血清转换，但在没有替诺福韦组患者。结论：病毒学应答和耐受性，在治疗慢性乙型肝炎的第一年，泰诺福韦和恩替卡韦之间没有差异显著。这两种药物是安全和有效的与乙肝病毒感染的患者。

咬牙硬挺

有这两种药是幸运啊

咬牙硬挺

有这两种药是幸运啊

咬牙硬挺

有这两种药是幸运啊

咬牙硬挺

有这两种药是幸运啊